Overview of FDA Medical Device Regulation and CDRH Role
A detailed guide to the FDA Center for Devices and Radiological Health (CDRH), covering device classification (Class I, II, III), regulatory pathways like 510(k) and PMA, and post-market surveillance.
Overview
Summary of this regulator or jurisdiction and how it relates to market access.
Overview of the FDA Center for Devices and Radiological Health (CDRH)
The Center for Devices and Radiological Health (CDRH) is the branch of the United States Food and Drug Administration (FDA) responsible for regulating firms that manufacture, repackage, relabel, and/or import medical devices sold in the United States. In addition, CDRH regulates radiation-emitting electronic products (such as lasers, x-ray systems, ultrasound equipment, microwave ovens and color televisions).
1. Medical Device Classification
The FDA classifies medical devices based on the risks associated with the device and the level of control necessary to provide a reasonable assurance of its safety and effectiveness.
[Image of FDA medical device classification system]
- Class I (Low Risk): Most Class I devices are exempt from premarket notification. Examples: Bandages, handheld surgical instruments.
- Class II (Moderate Risk): Most Class II devices require a Premarket Notification [510(k)]. Examples: Powered wheelchairs, infusion pumps.
- Class III (High Risk): Devices that support or sustain human life or present a potential, unreasonable risk of illness or injury. These require Premarket Approval (PMA). Examples: Heart valves, implanted cerebelar stimulators.
2. Regulatory Pathways to Market
[Image of the 510(k) and PMA regulatory pathways]
- Premarket Notification [510(k)]: A marketing submission made to the FDA to demonstrate that the device to be marketed is at least as safe and effective (substantially equivalent) to a legally marketed device (predicate device).
- Premarket Approval (PMA): The most stringent type of device marketing application. It must contain valid scientific evidence to assure that the device is safe and effective for its intended use(s).
- De Novo: A pathway for novel medical devices for which there is no legally marketed predicate device, but that are low to moderate risk.
- Humanitarian Device Exemption (HDE): For devices intended to benefit patients in the treatment or diagnosis of diseases or conditions that affect fewer than 8,000 individuals in the U.S. per year.
3. Post-Market Requirements
Once a device is on the market, the FDA continues to monitor its performance through:
- Medical Device Reporting (MDR): Mandatory reporting of adverse events by manufacturers, importers, and user facilities.
- Quality System Regulation (QSR): Requirements related to the methods used in, and the facilities and controls used for, the designing, manufacturing, packaging, labeling, storing, installing, and servicing of finished devices.
- Recalls and Safety Alerts: Monitoring device removals or corrections to protect public health.
[Image of the medical device lifecycle from R&D to post-market surveillance]
4. Digital Health and Innovation
The FDA's Digital Health Center of Excellence focuses on modernizing regulatory approaches for:
- Software as a Medical Device (SaMD)
- Artificial Intelligence and Machine Learning (AI/ML)
- Medical Device Cybersecurity
- Wireless Medical Devices
Articles & guides
Insight articles mapped to this region on ElendiLabs.
April 5, 2026
Proactive Regulatory Engagement and ISO Certification for AI-Powered Digital Mental Health Companion Platform
Early regulatory engagement with the FDA, combined with ISO 13485-certified quality management systems, 16 clinical trials involving over 1,800 participants, and real-world deployment experience enabled the development of fully automated AI-powered digital companions that deliver personalized, evidence-based chat-based support for anxiety and depression symptoms, broadening product offerings across adults, adolescents, and maternal health while exploring novel pathways from general wellness to potential FDA-cleared solutions to address surging mental health needs and provider shortages.
Read article →
April 5, 2026
Pioneering Interoperable Automated Insulin Delivery System Clearance Through FDA Expedited Component Pathway
Early FDA engagement on an expedited interoperable pathway for automated insulin delivery components enabled the first fully interoperable closed-loop automated insulin dosing app to achieve 510(k) clearance, transforming patient-led DIY innovation into a regulated solution that integrates independently reviewed continuous glucose monitors and pumps, providing greater choice for individuals with insulin-dependent diabetes while addressing safety concerns and streamlining future submissions as a predicate device.
Read article →
April 5, 2026
Proactive FDA Engagement for 510(k) Clearance of AI-Powered 3D Digital Breast Tomosynthesis Analysis Software
Early regulatory intelligence combined with proactive pre-submission engagement with the FDA, informed by prior lessons from mammography AI submissions, enabled the development and swift 510(k) clearance of an advanced AI algorithm designed to analyze 3D images generated by digital breast tomosynthesis equipment, delivering faster and more accurate breast cancer detection compared with conventional 2D mammography while meeting rigorous standards for accuracy, reliability, and repeatability.
Read article →
April 4, 2026
FDA Pre-Submission Engagement and Service-Based Reimbursement Model for EMG Biofeedback Digital Therapy Platform
Early FDA engagement and recognition of neuromuscular re-education as a reimbursable clinical service enabled 510(k) exempt status and breakthrough device designation for EMG-based therapies, facilitating EHR integration for direct prescription retrieval, reimbursement under four CPT codes and remote therapeutic monitoring codes, and deployment across health systems, ambulatory clinics, and home settings for conditions including stroke, chronic pain, pelvic health, and movement disorders.
Read article →
April 4, 2026
Pre-Submission FDA Engagement for 510(k) Clearance of Pediatric Wearable Remote Monitoring Platform
Early and iterative pre-submission meetings with the FDA enabled the development and 510(k) clearance of a miniaturized wearable monitoring bracelet and cloud-based analytics platform for out-of-hospital monitoring of newborns and children, addressing unique pediatric anatomical and physiological differences through US-specific clinical testing, gap analysis versus European data, and an exempt user fee, resulting in market access for remote physiologic monitoring and predictive health assessment to reduce hospitalizations.
Read article →
April 4, 2026
Early FDA Engagement Strategy for 510(k) Clearance of Multifunctional Wearable Digital Health Monitoring Platform
Early and iterative pre-submission engagement with multiple FDA review divisions enabled the successful development and 510(k) clearance of a full-stack, condition-agnostic digital health monitoring platform, supporting integration with third-party algorithms, remote physiologic monitoring in home-healthcare settings for individuals aged 18 and older, and validation of over 100 digital clinical measurements for research and clinical care.
Read article →
April 4, 2026
Navigating the US Medical Device Clinical Trial Landscape: FDA Rules Study Design and Best Practices
A complete practical roadmap for medical device sponsors covering FDA risk-based classification, IDE versus IRB pathways, tailored study design, site selection benchmarks, recruitment and retention strategies, remote monitoring implementation, change control processes, and how to leverage international data for faster US market entry while meeting all compliance requirements.
Read article →
April 3, 2026
Establishing Pharmaceutical-Grade Evidence for Novel Prescription Digital Therapeutics in Major Depressive Disorder
By engaging the FDA through pre-submission meetings and mirroring pharmaceutical-level evidence requirements, the regulatory pathway for a novel software-based prescription digital therapeutic overcame payer skepticism regarding shorter development timelines and different safety-efficacy standards, secured 510(k) clearance tailored to its distinctive cognitive-emotional capabilities for major depressive disorder, demonstrated no treatment-related adverse events when paired with antidepressant medication, and achieved strong psychiatrist endorsement that exclusive brain training improves outcomes beyond cognitive behavioral therapy alone.
Read article →
April 3, 2026
First FDA-Authorized AI Cardiac Ultrasound Software: Regulatory Strategy for Innovation and Access
The regulatory journey enabled the first FDA authorization for AI-enabled cardiac ultrasound software, addressing sonographer shortages by utilizing pre-submission meetings with physical demonstrations, breakthrough designation status, the De Novo pathway, and the pioneering approval of a predetermined change control plan to support iterative AI updates, hardware portability, and algorithm optimization while ensuring product safety and effectiveness.
Read article →
April 3, 2026
FDA Pre-Submission Meetings Enabling De Novo Authorization of Home-Based Virtual Reality Therapy for Chronic Lower Back Pain
Pre-submission meetings with the FDA enabled a developer of virtual reality therapeutics to leverage existing and new research, resulting in the first FDA-authorized in-home virtual reality treatment for chronic lower back pain that delivers clinically proven pain reduction through non-pharmacological cognitive behavioral mechanisms while securing payer coverage and patient access without out-of-pocket costs.
Read article →
April 3, 2026
Trial Master File Rescue and Reconstruction for Multi-Site Paper-Based Medical Device Clinical Study
A neglected Trial Master File for an ongoing paper-based medical device clinical study involving 15 sites across the US and EU was fully rescued through systematic reconstruction, gap analysis, document collection from multiple third parties and former CROs, creation of electronic TMF reference models, memos-to-file for unrecoverable items, restoration of site monitoring, subject follow-up for seven-year visits, and preparation for FDA audit, enabling the study to resume compliant operations with database lock readiness.
Read article →
April 3, 2026
Retrospective Clinical Study Management for Active Medical Device in Pancreatic Tumor Ablation
A retrospective clinical study for a 510(k)-cleared active medical device used in soft tissue tumor ablation collected unbiased safety and outcome data from 21 Stage III pancreatic cancer patients through prospective protocol design, independent third-party data collection, DSMB review by oncological surgeons, and independent radiologist imaging analysis, confirming device safety and supporting future Phase II prospective studies and regulatory submissions.
Read article →
April 3, 2026
FDA CAPA Investigation and Process Qualification Resolution Enabling Relaunch of Class III Spinal Implant Device After Manufacturing Relocation
A manufacturer relocating its Class III spinal implant production facility successfully resolved repeated Process Qualification failures through a comprehensive CAPA investigation involving full process mapping, surface contamination analysis via SEM EDS and FTIR, root cause identification, corrective actions, and validation updates, resulting in completed PQ, removal of sales restrictions, and product relaunch with enhanced quality system controls.
Read article →
April 3, 2026
Comprehensive FDA Inspection Preparation and Quality System Enhancement for Combination Product Implant Manufacturing
A European manufacturer of a long-term implant combination product containing an antibiotic successfully completed its first FDA inspection with only four minor observations and a Voluntary Action Indicated rating after a focused three-month preparation program that included baseline audits against 21 CFR 820 and 21 CFR 211, gap analysis, transition from EN ISO 13485:2013 to 2016, major updates to design control CAPA and process validation, complete Design History File reconstruction, and on-site inspection support as U.S. Agent.
Read article →
April 2, 2026
EN ISO 13485 Recertification Audit Preparation and Technical File Reconstruction for U.S. Based Medical Device and In Vitro Diagnostic Manufacturers
U.S.-based manufacturers of in vitro diagnostics and medical devices lacking internal audit resources successfully achieved EN ISO 13485 recertification by receiving expert supplementation of staff, conducting comprehensive baseline audits against 21 CFR 820 and EN ISO 13485 standards, performing detailed gap analyses, reconstructing technical files using standardized templates, redesigning design control and CAPA processes through flowcharting and custom SOPs, managing a full internal audit program with four targeted visits, and implementing monitored corrective actions that earned highly positive feedback from the Notified Body auditor.
Read article →
April 2, 2026
EN ISO 13485 Certification Process for Chinese Medical Device Manufacturers Entering the European Union Market
A China-based manufacturer of Class I through Class III implantable medical devices achieved EN ISO 13485 certification as an EU vendor within eight months by implementing a fully customized quality management system focused on supplier oversight, risk management per EN ISO 14971, technical file creation, labeling controls, and geographic coordination across China, Germany, and the United States, enabling a fully operational EU company with minimal internal resource consumption.
Read article →
April 2, 2026
Clinical Application Protocol Development for In Vitro Diagnostic Devices in Cancer Metastasis Research
Streamlined clinical application protocols for no-risk in vitro diagnostic devices enable sponsors to gather targeted clinician feedback on cancer metastasis pathways within specific cancer populations, providing structured responses to FDA information requests while minimizing regulatory steps, eliminating patient contact, and establishing a foundation for future clinical trials.
Read article →
April 2, 2026
FDA 510(k) Clearance for Medical Device-Drug Combination Product: Bone Cement with Antibiotic
A European manufacturer successfully obtained FDA 510(k) clearance in five months for a bone cement containing an antibiotic classified as a combination product. The regulatory strategy ensured full compliance with both medical device QSR (21 CFR 820) and pharmaceutical GMP (21 CFR 211) requirements through pre-submission planning, formulation and labeling review, preclinical testing coordination, and direct FDA engagement that confirmed flexibility on antibiotic concentrations and test requirements.
Read article →
April 2, 2026
Repairing an FDA IDE Clinical Study: Restoring Compliance for an Investigational Medical Device Trial
An FDA IDE clinical study for an investigational medical device lost oversight after acquisition, leading to disorganized files, outdated TMF, no DSMB, missing radiographic analyses, and poor site communication. Rapid intervention restored FDA communication, implemented full data cleaning and query resolution, reestablished DSMB for AE adjudication, rebuilt the TMF using the reference model, resumed radiographic core lab work, and strengthened site monitoring, achieving full compliance and positioning the study for database lock and PMA submission within two years.
Read article →
April 1, 2026
US Army Secures FDA 510(k) Clearance for APPRAISE-HRI Smartphone Machine Learning Hemorrhage Detection SaMD
The US Army secured FDA 510(k) clearance for APPRAISE-HRI, a smartphone-based machine learning SaMD designed to triage soldiers with internal hemorrhaging in the field, by developing a comprehensive regulatory strategy, implementing a targeted quality management system, conducting independent clinical validation using existing trauma databases, performing full cybersecurity testing including threat modeling and penetration testing, and successfully negotiating FDA feedback through Q-submissions without major software changes or additional studies.
Read article →
April 1, 2026
Cybersecurity Standards for Software Medical Devices: Key Requirements in the United States, Canada, European Union, and United Kingdom
Cybersecurity standards for software medical devices mandate security-by-design principles, comprehensive lifecycle risk management, premarket documentation such as threat modeling and software bills of materials, rigorous testing, and continuous postmarket surveillance across the United States, Canada, European Union, and United Kingdom to safeguard patient safety against evolving cyber threats.
Read article →
March 30, 2026
Local Testing Support for Generic Radiopharmaceuticals During ANDA Registration in China
A global radiopharmaceutical manufacturer successfully completed mandatory local testing of two generic drugs at the official Chinese laboratory as part of its ANDA registration, overcoming challenges in sample importation, customs clearance, and analytical method transfer.
Read article →
March 30, 2026
Harmonized Global Registration of a Class II Hemostatic Valve in Six Key Markets
A US medical device manufacturer successfully registered its Class II hemostatic valve in Australia, Brazil, China, India, Pakistan, and Russia by leveraging existing US, Canadian, and EU approvals and applying a harmonized regulatory strategy with core dossier preparation and efficient project management.
Read article →
February 25, 2026
U.S. FDA Drug Development and Approval Process Overview
The U.S. FDA’s Center for Drug Evaluation and Research (CDER) ensures marketed drugs are safe and effective by reviewing sponsor-submitted data in applications such as IND for clinical trials, NDA for new drugs, ANDA for generics, BLA for biologics, and OTC monographs or NDAs for nonprescription products.
Read article →
February 24, 2026
U.S. FDA's Leadership in Developing APEC Supply Chain Security Toolkit for Medical Products
The U.S. FDA leads global collaboration with APEC economies, industry, academics, and regulators to create and maintain the Supply Chain Security Toolkit for Medical Products, providing training materials, best practices, and tools across 10 categories to prevent, detect, and respond to counterfeit or substandard medical products throughout the supply chain lifecycle.
Read article →
February 23, 2026
U.S. FDA Initiatives to Ensure Drug Supply Chain Integrity
The U.S. FDA safeguards the drug supply chain—one of the world’s safest—through the Drug Supply Chain Security Act (DSCSA) for electronic tracing, rapid reporting of illegitimate products, anti-counterfeiting guidance, public education campaigns like BeSafeRx and Know Your Source, and international partnerships to prevent counterfeit, stolen, or harmful drugs from reaching patients.
Read article →
February 22, 2026
U.S. FDA Office of New Drugs (OND) Organization, Functions, and Key Resources
The FDA’s Office of New Drugs (OND) within CDER reviews new drug and biologic applications, provides regulatory oversight for investigational studies, sets policy for efficient approvals, and maintains key databases such as Drugs@FDA and postmarket requirements, operating through eight review offices with 27 divisions focused on specific therapeutic areas.
Read article →
February 20, 2026
FDA Postmarketing Requirements and Commitments Frequently Asked Questions
The U.S. FDA provides FAQs on postmarketing requirements (PMRs) and commitments (PMCs) for drugs and biologics, covering reporting, updates, statuses, and distinctions introduced by FDAAA, with explanations on annual reports and database searches.
Read article →
February 19, 2026
FDA Postmarketing Requirements and Commitments Reports Overview
The U.S. FDA publishes annual reports in the Federal Register and to Congress on postmarketing requirements (PMRs) and commitments (PMCs) for drugs and biologics, tracking statuses like pending, ongoing, delayed, and fulfilled, with a focus on backlog reviews since FDAAA in 2007.
Read article →
February 18, 2026
FDA Postmarketing Requirements and Commitments for Drugs and Biologics
The U.S. FDA requires or commits applicants to conduct post-approval studies and clinical trials to gather additional safety, efficacy, or optimal use data for drugs and biologics, with searchable databases and FAQs available.
Read article →
February 17, 2026
FDA Postmarketing Requirements and Commitments Status and Fulfillment Categories
The U.S. FDA defines seven status categories for postmarketing requirements (PMRs) and commitments (PMCs)—Pending, Ongoing, Delayed, Terminated, Submitted, Fulfilled, and Released—to track study progress and fulfillment, with fulfilled and released items displayed in the database for no more than one year.
Read article →
February 17, 2026
FDA's Upcoming Product-Specific Guidances for Generic Drug Development
The U.S. FDA publishes planned new and revised product-specific guidances (PSGs) quarterly to support generic drug development, detailing bioequivalence studies for complex and non-complex products, with categories for revisions and fiscal year publication plans.
Read article →
February 16, 2026
U.S. FDA Human Drug Import Requirements and Procedures
The U.S. FDA ensures imported human drugs meet safety, effectiveness, and quality standards through reviews, sampling, and enforcement, refusing non-compliant shipments for adulteration, misbranding, or lack of approval, with specific pathways for foreign-market drugs and personal imports.
Read article →
February 15, 2026
Interpreting FDA Returns on Electronic Certificate of Pharmaceutical Product Applications
The U.S. FDA returns eCPP applications for reasons like unacceptable CGMP, missing inspections, or mismatched product details, providing applicants a chance to correct via 'Return for Action' requests before cancellation after two attempts or non-response within three days.
Read article →
February 13, 2026
U.S. FDA Human Drug Export Resources for Foreign Governments
The U.S. FDA provides foreign governments with eCPP issuance (over 8,500 annually), WHO-harmonized certification, public inspection dashboards, Orange Book verification, and eCPP authentication tools to facilitate safe drug imports from the United States.
Read article →
February 12, 2026
U.S. FDA Human Drug Export Certificate Application Instructions Using CDEReCATS
The U.S. FDA’s CDEReCATS online portal enables U.S. facilities to request Certificates of Pharmaceutical Product or CGMP declarations for human drug exports, providing guided applications, real-time validation, email status updates, and possible faster processing when a standard CPP is required by foreign regulators.
Read article →
February 11, 2026
Exporting Investigational New Drugs from the U.S. under FDA Regulations
The U.S. FDA permits export of investigational new drugs (INDs) to listed countries without prior approval if compliant with importing country laws, or to other countries under specific mechanisms in 21 CFR 312.110(b) with notification and recordkeeping requirements.
Read article →
February 11, 2026
Export Requirements for Unapproved Human Drugs by the U.S. FDA
Under section 802 of the FD&C Act, the U.S. FDA permits export of unapproved human drugs that comply with the importing country’s laws and hold valid marketing authorization in listed countries (Australia, Canada, Israel, Japan, New Zealand, Switzerland, South Africa, EU/EEA), requiring simple notification, recordkeeping, and compliance with labeling and CGMP where applicable.
Read article →
February 10, 2026
U.S. FDA Export Requirements for Human Drugs
The U.S. FDA regulates commercial exports of human drugs under FD&C Act sections 801 and 802, requiring compliance with labeling, CGMP, and recordkeeping for approved and certain unapproved drugs, while personal use exports fall outside FDA jurisdiction.
Read article →
February 9, 2026
Electronic Certificates of Pharmaceutical Product (eCPP) for Human Drug Exports by the U.S. FDA
The U.S. FDA issues electronic Certificates of Pharmaceutical Product (eCPP) in WHO format via CDEReCATS to foreign regulators confirming U.S. marketing status and CGMP compliance for exported drugs when a standard CPP is not accepted, processed within 20 days for a fee up to $175 and valid 24 months.
Read article →
February 8, 2026
Current Good Manufacturing Practice Declarations for Human Drug Exports by the U.S. FDA
The U.S. FDA issues CGMP declarations to foreign regulators confirming the compliance status of inspected U.S. drug establishments for export purposes when a Certificate of Pharmaceutical Product is not accepted, processed via CDEReCATS within 30 days.
Read article →
February 7, 2026
Electronic Drug Registration and Listing Instructions with the U.S. FDA
The FDA requires drug establishments to register annually and list their drugs electronically through eDRLS using SPL format via ESG, ensuring accurate identification and regulatory compliance for drugs distributed in the United States.
Read article →
December 16, 2025
The Evolution of ISO 13485: From Basic QMS to Global Regulatory Alignment
ISO 13485 has evolved from early EN standards into the global benchmark for medical device quality management. The current 2016 version, focused on risk management and lifecycle control, has been reconfirmed until 2030. A major milestone in this evolution is the US FDA's transition from the Quality System Regulation (QSR) to the Quality Management System Regulation (QMSR), which fully aligns US requirements with ISO 13485:2016.
Read article →
December 16, 2025
FDA Recall Bottlenecks: GAO Report Highlights Staffing Gaps and Oversight Delays
A new report from the US Government Accountability Office (GAO) reveals that staffing shortages at the FDA are significantly slowing medical device recall oversight. With the average time to formally close a recall extending to 260 days—well beyond the 90-day target—the report warns that critical safety tasks are being deprioritized. Key findings include a massive backlog in recall terminations and the increasing complexity of medtech recalls compared to pharmaceuticals.
Read article →
December 7, 2025
FDA Modernizes Medical Device Submissions: Key Updates to the eCopy Guidance
The FDA has released an updated guidance for the eCopy Program for Medical Device Submissions, marking the first significant refresh since 2020. This update reflects a strategic shift toward fully electronic review processes, aligning with eSTAR and structured eSubmissions. Key changes include updated technical requirements for PDFs, a stronger emphasis on standalone submissions, and critical validation reminders to prevent review delays.
Read article →
November 6, 2025
Technical Overview: The FDA ANDA Process for Generic Drug Approval
The Abbreviated New Drug Application (ANDA) is the FDA pathway (Section 505(j)) for generic drug approval, requiring demonstration of **pharmaceutical equivalence** and **bioequivalence (BE)** to a Reference Listed Drug (RLD). The process involves RLD identification, Q1/Q2 formulation, BE studies, stability testing, and eCTD submission under GDUFA.
Read article →
October 2, 2025
US Medical Device Clearance: The Predicate Pathway and FDA's Regulatory Philosophy
The US FDA emphasizes different regulatory barriers than the EU. The **510(k) pathway** often allows clearance based on demonstrating **substantial equivalence** to a predicate device, representing a distinct philosophy focused on comparative safety and effectiveness rather than the continuous, stricter clinical evaluation required by the EU MDR.
Read article →
September 20, 2025
The Path to Approval: Navigating the New Drug Application (NDA) Journey
Bringing a new drug from the lab to the patient is a highly regulated journey. This article outlines the six critical steps of the New Drug Application (NDA) process, from preclinical pharmacology and the Investigational New Drug (IND) phase to Phase I-III clinical trials and the final FDA review. Understanding the CTD format and CMC requirements is essential for ensuring that only safe, effective medicines reach the market.
Read article →
August 18, 2025
Understanding the Drug Master File (DMF) for Pharmaceutical APIs
A Drug Master File (DMF) is a confidential regulatory document containing proprietary details on an Active Pharmaceutical Ingredient's (API) manufacturing and quality. It allows drug product manufacturers to reference API data via a Letter of Authorization (LOA) without exposing trade secrets. This article breaks down the DMF purpose and its structure according to ICH CTD standards, including manufacturing, characterization, and stability data.
Read article →
July 20, 2025
Decoding FDA NDA Classification Codes: A Strategic Guide for Regulatory Affairs
FDA NDA classification codes (Types 1-10) are essential for defining the innovation level, review pathways, and data requirements for drug approvals in the US. From Type 1 New Molecular Entities (NME) to Type 8 Rx-to-OTC switches, understanding these classifications is a cornerstone of regulatory strategy and lifecycle management. This article provides a comprehensive breakdown of all ten types and explains why they matter for successful market access.
Read article →
April 2, 2025
How Long is the FDA Review Process for 510(k) Medical Device Submissions? (MDUFA III Goals)
The FDA's goal, per MDUFA III, is to issue a final clearance decision for most 510(k) submissions within **90 calendar days**. Key milestones include acceptance review within 15 days and substantive review decisions within 60 days, providing manufacturers with a predictable communication timeline.
Read article →
March 2, 2025
Understanding the FDA Q-Submission (Q-Sub) Process and Pre-Submission Guidance
The FDA's Q-Submission (Q-Sub) process, primarily used as a **Pre-Submission (Pre-Sub)**, allows medical device manufacturers to receive formal, non-mandatory regulatory feedback from FDA experts *before* submitting their 510(k), PMA, or IDE application. This early dialogue is crucial for novel or high-risk devices.
Read article →
February 2, 2025
US FDA Medical Device Classification: Risk-Based System and Pathways for Novel Devices
The US FDA classifies medical devices into Class I, II, or III based on risk, using a predicate-based system. Most Class II devices require a 510(k), while Class III requires Premarket Approval (PMA). Novel devices lacking a predicate may pursue classification via a 513(g) Request or the De Novo pathway to avoid automatic Class III status.
Read article →
January 2, 2025
US FDA Clearance Pathways: Classification, QSR, and the 510(k) / PMA Process
All medical and IVD devices for sale in the US must follow the FDA's regulatory process, which involves risk-based classification (Class I, II, III), compliance with the Quality System Regulation (QSR), and securing premarket authorization through 510(k) or Premarket Approval (PMA).
Read article →
December 2, 2024
US FDA Establishment Registration and Device Listing (FURLS) Requirements
Annual **Establishment Registration** and **Device Listing** with the US FDA is mandatory for most facilities involved in manufacturing, importing, or reprocessing devices for the US market. Registration is completed via the online **FURLS** system, and listing is generally required unless the entity is an Initial Importer.
Read article →